Joy C Yang (Joy Yang)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 17

Top Topics

Radical Prostatectomy

Protein Protein

Top Venues

Research square

Nature communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Pengfei Xu, Joy C Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang, Christopher Nip, Yuqiu Shen, Oleta T Johnson, Gabriela Grigorean, Brett S Phinney, Liangren Liu, Qiang Wei, Eva Corey, Clifford G Tepper, Hong-Wu Chen, Christopher P Evans, Marc A Dall'Era, Allen C Gao, Jason E Gestwicki, Chengfei Liu
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature communications 15 (1) (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene (2024)
Pengfei Xu, Joy C Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang, Christopher Nip, Yuqiu Shen, Oleta T Johnson, Gabriela Grigorean, Brett S Phinney, Liangren Liu, Qiang Wei, Eva Corey, Clifford G Tepper, Hong-Wu Chen, Christopher P Evans, Marc A Dall'Era, Allen C Gao, Jason E Gestwicki, Chengfei Liu
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature communications 15 (1) (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene (2024)
Pengfei Xu, Joy C Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang, Christopher Nip, Yuqiu Shen, Oleta T Johnson, Gabriela Grigorean, Brett S Phinney, Liangren Liu, Qiang Wei, Eva Corey, Clifford G Tepper, Hong-Wu Chen, Christopher P Evans, Marc A Dall'Era, Allen C Gao, Jason E Gestwicki, Chengfei Liu
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature communications 15 (1) (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Shu Ning, Chengfei Liu, Wei Lou, Joy C Yang, Alan P Lombard, Leandro S D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R Leslie, Masuda Sharifi, Christopher P Evans, Allen C Gao
Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Molecular cancer therapeutics 21 (10) (2022)